Forest Laboratories (FRX) 99.00 $FRX
Adamas Pharmaceuticals Provides Review of 2014 and Previews Upcoming Business Drivers
GlobeNewswire - Sun Jan 11, 6:00PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today provided a recap of its 2014 achievements and a preview of its near-term priorities. Adamas, which develops new treatments for neurological disorders, utilizes its technology platform to improve the pharmacokinetic profiles of approved drugs, alone and in fixed-dose combinations. The company's diversified business model includes forming partnerships to improve existing brands and developing wholly owned products. Its partnership to improve existing brands, which is currently focused on Alzheimer's disease, is with Forest Laboratories, a subsidiary of Actavis plc. Adamas' wholly owned product portfolio includes ADS-5102, now in late-stage clinical development for levodopa-induced dyskinesia (LID), a movement disorder associated with Parkinson's disease.
ADMS: 16.98 (+0.03), FRX: 99.00 (-0.77)
Adamas Pharmaceuticals wins USD30m milestone payment from Actavis for Namzaric
M2 - Fri Jan 09, 6:25AM CST
Specialist pharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) revealed on Thursday the receipt of USD30m milestone payment from Forest Laboratories Holdings, a subsidiary of Actavis.
ADMS: 16.98 (+0.03), FRX: 99.00 (-0.77)
Adamas Pharmaceuticals Receives $30 Million Milestone Payment From Actavis
GlobeNewswire - Thu Jan 08, 3:06PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) announced today that it has received a $30 million milestone payment from Forest Laboratories Holdings Limited, a subsidiary of Actavis plc, based on the recent FDA approval of Namzaric(TM), formerly known as MDX-8704. Adamas developed a fixed-dose combination of memantine hydrochloride extended-release (a NMDA receptor antagonist) and donepezil hydrochloride (an acetylcholinesterase inhibitor) initially, and Namzaric is the first and only such fixed-dose combination approved by the FDA for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on memantine hydrochloride and donepezil hydrochloride. Namzaric is covered by multiple Adamas US patents that extend up to 2029.
ADMS: 16.98 (+0.03), FRX: 99.00 (-0.77)
SCYNEXIS, Inc. Announces Appointment of Two Seasoned Industry Professionals to Its Board of Directors
GlobeNewswire - Wed Dec 03, 8:24AM CST
SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the appointment of Guy Macdonald and Marco Taglietti, M.D., to its Board of Directors. Mr. Macdonald currently serves as President and Chief Executive Officer of Tetraphase Pharmaceuticals, Inc., and Dr. Taglietti is former Executive Vice President of Research and Development and Chief Medical Officer of Forest Laboratories, Inc. In addition, the Company announced that Mounia Chaoui, Ph.D., has resigned from the Board of Directors.
TTPH: 35.18 (-0.73), SCYX: 9.48 (+0.07), FRX: 99.00 (-0.77)
Research and Markets: Forest Labs Clinical Development Profile 2014
Business Wire - Mon Nov 03, 12:25PM CST
Research and Markets (http://www.researchandmarkets.com/research/brrhxs/forest_labs) has announced the addition of the "Forest Labs Clinical Development Profile" report to their offering.
FRX: 99.00 (-0.77)
Forest Labs Clinical Development Profile 2014
M2 - Mon Nov 03, 9:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/shvw4c/forest_labs) has announced the addition of the "Forest Labs Clinical Development Profile" report to their offering. This report provides a thorough analysis of Forest Laboratories' R&D pipeline, clinical trial activity, patents, FDA submissions, and includes profiles of Forest's key products. In Forest's January 2014 financial conference call they noted that Research and Development spending for the current quarter was approximately $220 million as compared to $325 million reported in the third quarter last year, a reported decrease of 33%,' explained Andrew Schafer, President of ISR. We certainly did not see Forest's recent acquisition of Aptalis coming or the more recent offer by Actavis to buy Forest Labs for $25 Billion. However, we did realize that Forest was a company in play, Schafer continued. The report provides pharmaceutical companies and service providers with a look into Forest's individual drug sales and company financial condition over the past four years, the number, length, and patient enrollment of clinical trials segmented by phase and trial type, and Forest's R&D pipeline with mechanism of action identified. This data will help service providers better understand Forest's clinical pipeline while giving sponsors an idea of how these competing compounds may affect the launch of similar products. Key Topics Covered: 1. Copyright and Usage Guidelines 2. Background and strategy 3. Financial condition 4. R&D pipeline overview 5. Clinical trial activity 6. Patents 7. FDA submissions 8. Key product profiles 9. Summary For more information visit http://www.researchandmarkets.com/research/sh...orest_labs
FRX: 99.00 (-0.77)
Helius Medical Technologies Appoints Dr. Jonathan Sackier as Chairman of Scientific Advisory Board
ACCESSWIRE - Mon Oct 27, 12:30PM CDT
Newtown, PA / ACCESSWIRE / October 27, 2014 / Helius Medical Technologies, Inc. (CSE: HSM) ("HMT", "Helius" or the "Company"
a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, is pleased to announce today that noted British surgeon Dr. Jonathan Sackier has agreed to serve as Chairman of the company's newly formed Scientific Advisory Board.
FRX: 99.00 (-0.77)
Thyroid Cancer Market Analysis - API Manufacturers and Phase III Pipeline Assessment 2014-2015
M2 - Thu Oct 02, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5sgp9d/thyroid_cancer) has announced the addition of the "Thyroid Cancer Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Thyroid Cancer- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Exelixis, Inc. - Pfizer Inc. - Genzyme Corporation - Bracco Diagnostics Inc. - Mallinckrodt plc - Sandoz Inc. - Forest Laboratories, Inc. - Institut Biochimique SA - Jubilant DraxImage Inc. For more information visit http://www.researchandmarkets.com/research/5s...oid_cancer
PFE: 34.64 (-0.23), FRX: 99.00 (-0.77), EXEL: 2.48 (+0.20)
Alcohol Addiction Market Analysis - Global API Manufacturers and Phase III Pipeline Assessment 2014-2015
M2 - Thu Oct 02, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grf3gh/alcohol) has announced the addition of the "Alcohol Addiction- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Alcohol Addiction- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Alkermes Plc - Duramed Pharmaceuticals, Inc. - Odyssey Pharmaceuticals, Inc. - Teva Pharmaceuticals USA, Inc. - Forest Laboratories, Inc. - Valeant Pharmaceuticals International, Inc. For more information visit http://www.researchandmarkets.com/research/grf3gh/alcohol
ALKS: 71.40 (-1.89), FRX: 99.00 (-0.77), VRX.TO: 207.95 (-1.47)
Influenza A Infections Market Analysis 2014-2015 - API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Oct 02, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tm72pp/influenza_a) has announced the addition of the "Influenza A Infections Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Influenza A Infections- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Forest Laboratories, Inc. - Caraco Pharmaceutical Laboratories, Ltd. - Endo Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tm...nfluenza_a
ENDP: 84.01 (+1.12), FRX: 99.00 (-0.77)
Depression Market Analysis - Global API Manufacturers and Phase III Pipeline Assessment, 2014-2015
M2 - Thu Oct 02, 3:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f52zs9/depression_market) has announced the addition of the "Depression Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Depression Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Forest Laboratories, Inc. - Pfizer Inc. - Abbott Laboratories - Sanofi - Eli Lilly and Company - Bristol-Myers Squibb Company - sanofi-aventis U.S. LLC. - Validus Pharmaceuticals LLC - AstraZeneca PLC - Valeant Pharmaceuticals International, Inc. - Teva Pharmaceutical Industries Limited - Lilly USA, LLC - Janssen Pharmaceutical Ltd - Merck & Co., Inc. - Otsuka Pharmaceutical Co., Ltd. - Teva Pharmaceuticals USA, Inc. - Novartis AG - F. Hoffmann-La Roche Ltd. - AstraZeneca Pharmaceuticals, LP - Baxter Healthcare Corporation - GlaxoSmithKline LLC - Solvay Pharmaceuticals, Inc. - Roxane Laboratories, Inc. - Bayer HealthCare Pharmaceuticals Inc. - Solvay Pharma Inc. - New River Pharmaceuticals, Inc. - GlaxoSmithKline plc - Bioniche Pharma Group Limited - Dr. Reddy's Laboratories Limited - Orchid Chemicals & Pharmaceuticals Ltd For more information visit http://www.researchandmarkets.com/research/f5...ion_market
ABT: 46.09 (+0.87), PFE: 34.64 (-0.23), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), FRX: 99.00 (-0.77), VRX.TO: 207.95 (-1.47), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Network with Astellas, GSK, J&J, and the National Pharmacy Association | European Pharmaceutical P&R 2014
PRWeb - Sat Sep 27, 3:01AM CDT
Just under 3 weeks remain until the doors open to host the popular industry conference on European Pharmaceutical Pricing and Reimbursement. this global event will feature attendees from Belgium, Czech Republic, Denmark, France, Germany, Italy, Netherlands, Sweden, Switzerland, United Kingdom and USA.
JNJ: 99.62 (+1.18), FRX: 99.00 (-0.77)
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023
M2 - Thu Sep 25, 5:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9vx7ff/pharmapoint) has announced the addition of the "PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023" report to their offering. Product Launches and Patent Expiries to Push Major Depressive Disorder Treatment Market through Fluctuating Growth Period by 2023 This report provides an overview of Major Depressive Disorder (MDD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis and current treatment options. The key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the MDD therapeutics market. The therapeutics market for Major Depressive Disorder (MDD) will face a dynamic phase up until the end of 2023, thanks to the potential launch of new treatments following the patent expirations of top-selling products, says a new report from research and consulting firm The authors. According to the company's latest report*, the MDD treatment market achieved sales of approximately $9.3 billion in 2013 across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan) and Australia. These sales will witness minimal growth by the end of 2023, reaching an estimated $9.7 billion, at a Compound Annual Growth Rate (CAGR) of 0.39%. However, The authors forecasts that the market value will first undergo a decline until 2017, with sales dropping to $7.3 billion. This can be attributed mainly to the expirations of patents for Eli Lilly's Cymbalta, Otsuka Pharmaceutical/BMS' Abilify and AstraZeneca's Seroquel XR. The authors states that there are already seven products in the late-stage pipeline that could enter the MDD market during the forecast period. These include adjunctive therapies, such as Otsuka/Lundbeck's brexpiprazole, Forest (Actavis)/Gedeon Richter/Mitsubishi Tanabe Pharma's cariprazine, Alkermes's ALKS-5461 and Naurex's GLYX-13, along with antidepressant therapies, including Euthymics Bioscience's amitifadine, Lundbeck/Takeda's tedatioxetine and e-Therapeutics' ETS6103. Koutsokeras continues: All seven of these pipeline drugs show promise as safer and more efficacious treatments for MDD patients, while GLYX-13 and ETS6103 in particular boast the potential to provide rapid antidepressant effects. With their ability to address some of the MDD treatment market's key unmet needs, we believe that these products' launches could well spark its return to growth in 2018. Other driving factors behind the reversal in its decline will be the increasing uptake of Lundbeck/Takeda's Brintellix, combined with the expanding number of MDD prevalent cases that we expect to see by the end of 2023. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview - Etiology and Pathophysiology - Classification - Symptoms and Subtypes of Major Depressive Disorder - Prognosis - Quality of Life 4 Epidemiology - Risk Factors and Comorbidities - Global and Historical Trends - Forecast Methodology - Epidemiological Forecast for MDD (2013-2023) 5 Disease Management - Diagnosis - Treatment Guidelines and Leading Prescribed Drugs - Clinical Practice 6 Competitive Assessment - Lexapro (Escitalopram) - Viibryd (Vilazodone) - Other Selective Serotonin Reuptake Inhibitors - Effexor (Venlafaxine) - Cymbalta (Duloxetine) - Pristiq (Desvenlafaxine) - Fetzima (Levomilnacipran) - Savella (Milnacipran) - Norepinephrine-Dopamine Reuptake Inhibitors - Noradrenaline and Specific Serotonergic Antidepressants - Monoamine Oxidase Inhibitors - Tricyclic Antidepressants - Brintellix (Vortioxetine) - Abilify (Aripiprazole) - Seroquel XR (Quetiapine) 7 Unmet Needs and Opportunities - More Effective Pharmacotherapies - More Favorable Side Effect Profiles - Rapid Onset of Antidepressant Effects - Personalized Treatment Approach 8 Pipeline Assessment - Brexpiprazole (OPC-34712) - Cariprazine (RGH-188) - ALKS-5461 - Amitifadine (EB-1010) - GLYX-13 - Tedatioxetine (Lu AA24530) - ETS6103 - Other Drugs in Development 9 Current and Future Players - Lundbeck - Forest Laboratories (Actavis) - Eli Lilly - Pfizer - Otsuka Pharmaceutical - AstraZeneca - Takeda Pharmaceutical - Alkermes - Euthymics Bioscience - Naurex - e-Therapeutics 10 Market Outlook - Global - US - France - Germany - Italy - Spain - UK - Japan - Australia 11 Appendix For more information visit http://www.researchandmarkets.com/research/9v...harmapoint
LLY: 70.56 (+0.03), ALKS: 71.40 (-1.89), FRX: 99.00 (-0.77)
Acute Inflammation Therapeutics Pipeline Report 2014 - 9 Companies & 10 Drug Profiles
M2 - Wed Sep 10, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/849tzx/acute) has announced the addition of the "Acute Inflammation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Inflammation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - BioLineRx, Ltd. - Actelion Ltd - Forest Laboratories, Inc. - Italfarmaco S.p.A. - Alligator Bioscience AB - Anacor Pharmaceuticals, Inc. - Omeros Corporation - Dompe Farmaceutici S.p.A. - Peptinnovate Limited Drug Profiles - ACT-389949 - ATL-1222 - CGEN-856 - ADC-1004 - DF-2156A - Selective Inhibitor of Pro Inflammatory Cytokine - AN-3485 - PIN-201104 - Small Molecule Targeting GPR32 for Acute Inflammation - Distamycin Derivatives For more information visit http://www.researchandmarkets.com/research/849tzx/acute
ANAC: 40.76 (-0.07), FRX: 99.00 (-0.77), OMER: 20.63 (+0.13)
Why Endo International Can Deliver Solid Rewards With Minimal Risk
at The Street - Tue Sep 02, 1:31PM CDT
With the recent deal for DAVA, Endo is now one of the best health care stocks to own.
ENDP: 84.01 (+1.12), MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58), FRX: 99.00 (-0.77)
RiverVest Venture Partners' Otonomy Completes $100 Million Initial Public Offering
Business Wire - Wed Aug 13, 9:23AM CDT
Otonomy, a RiverVest Fund II portfolio company that develops drug therapies for the inner and middle ear, announced today its $100 million initial public offering.
BSX: 14.98 (+0.24), ABT: 46.09 (+0.87), BCR: 175.38 (+0.50), PFE: 34.64 (-0.23), FRX: 99.00 (-0.77), OTIC: 31.14 (+0.13)
The Impact of Genericization in the Unipolar Depression Market Will be Tempered by the Continued Uptake of Novel Antidepressants and Antipsychotics
PR Newswire - Wed Aug 13, 9:00AM CDT
Decision Resources Group finds that in the unipolar depression* market, the expanding use of two recently approved therapies--Lundbeck/Takeda Pharmaceutical's Brintellix (vortioxetine), Actavis (formerly Forest Laboratories)/Pierre Fabre's Fetzima (levomilnacipran ER)--together with the forecasted launch of Otsuka Pharmaceutical/Lundbeck's brexpiprazole in the major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will offset a steep near-term decline in sales resulting from the loss of market exclusivity for the two key drugs prescribed for unipolar depression--duloxetine (Eli Lilly/Shionogi's Cymbalta/Xeristar, generics) and the atypical antipsychotic Abilify (Bristol-Myers Squibb/Otsuka Pharmaceutical's aripiprazole). By 2023, total major-market sales for unipolar depression will reach under $10 billion.
LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), FRX: 99.00 (-0.77)
Sponsor And CRO Finalists Announced For Annual Society For Clinical Research Sites Eagle Award
PR Newswire Europe - Mon Aug 11, 11:30AM CDT
- AstraZeneca, Boehringer Ingelheim, Eli Lilly & Company, Ferring Pharmaceuticals, Inc., Forest Laboratories, Inc., GlaxoSmithKline, Novartis, Novo Nordisk, Pearl Therapeutics, Pfizer, Sanofi, Chiltern International, ICON plc, INC Research, inVentiv Health, Parexel International, Pharmaceutical Research Associates (PRA), Quintiles, and Target Health Inc.
NVO: 43.76 (+0.61), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), FRX: 99.00 (-0.77), NVS: 102.20 (-0.17)
Adamas Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 07, 3:44PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported net income attributable to common stockholders of $16.4 million, or $0.88 per share on a fully diluted basis, for the quarter ended June 30, 2014. In the same period last year, the company reported a net loss attributable to common stockholders of $3.4 million, or $0.35 per share on a fully diluted basis. The difference between the two periods was primarily the result of the recognition of revenue associated with the collaboration with Forest Laboratories, Inc. (acquired by Actavis plc in July 2014).
ADMS: 16.98 (+0.03), FRX: 99.00 (-0.77)
Adamas Pharmaceuticals Provides Review of 2014 and Previews Upcoming Business Drivers
GlobeNewswire - Sun Jan 11, 6:00PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today provided a recap of its 2014 achievements and a preview of its near-term priorities. Adamas, which develops new treatments for neurological disorders, utilizes its technology platform to improve the pharmacokinetic profiles of approved drugs, alone and in fixed-dose combinations. The company's diversified business model includes forming partnerships to improve existing brands and developing wholly owned products. Its partnership to improve existing brands, which is currently focused on Alzheimer's disease, is with Forest Laboratories, a subsidiary of Actavis plc. Adamas' wholly owned product portfolio includes ADS-5102, now in late-stage clinical development for levodopa-induced dyskinesia (LID), a movement disorder associated with Parkinson's disease.
ADMS: 16.98 (+0.03), FRX: 99.00 (-0.77)
Adamas Pharmaceuticals wins USD30m milestone payment from Actavis for Namzaric
M2 - Fri Jan 09, 6:25AM CST
Specialist pharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) revealed on Thursday the receipt of USD30m milestone payment from Forest Laboratories Holdings, a subsidiary of Actavis.
ADMS: 16.98 (+0.03), FRX: 99.00 (-0.77)
Adamas Pharmaceuticals Receives $30 Million Milestone Payment From Actavis
GlobeNewswire - Thu Jan 08, 3:06PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) announced today that it has received a $30 million milestone payment from Forest Laboratories Holdings Limited, a subsidiary of Actavis plc, based on the recent FDA approval of Namzaric(TM), formerly known as MDX-8704. Adamas developed a fixed-dose combination of memantine hydrochloride extended-release (a NMDA receptor antagonist) and donepezil hydrochloride (an acetylcholinesterase inhibitor) initially, and Namzaric is the first and only such fixed-dose combination approved by the FDA for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on memantine hydrochloride and donepezil hydrochloride. Namzaric is covered by multiple Adamas US patents that extend up to 2029.
ADMS: 16.98 (+0.03), FRX: 99.00 (-0.77)
SCYNEXIS, Inc. Announces Appointment of Two Seasoned Industry Professionals to Its Board of Directors
GlobeNewswire - Wed Dec 03, 8:24AM CST
SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the appointment of Guy Macdonald and Marco Taglietti, M.D., to its Board of Directors. Mr. Macdonald currently serves as President and Chief Executive Officer of Tetraphase Pharmaceuticals, Inc., and Dr. Taglietti is former Executive Vice President of Research and Development and Chief Medical Officer of Forest Laboratories, Inc. In addition, the Company announced that Mounia Chaoui, Ph.D., has resigned from the Board of Directors.
TTPH: 35.18 (-0.73), SCYX: 9.48 (+0.07), FRX: 99.00 (-0.77)
Research and Markets: Forest Labs Clinical Development Profile 2014
Business Wire - Mon Nov 03, 12:25PM CST
Research and Markets (http://www.researchandmarkets.com/research/brrhxs/forest_labs) has announced the addition of the "Forest Labs Clinical Development Profile" report to their offering.
FRX: 99.00 (-0.77)
Forest Labs Clinical Development Profile 2014
M2 - Mon Nov 03, 9:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/shvw4c/forest_labs) has announced the addition of the "Forest Labs Clinical Development Profile" report to their offering. This report provides a thorough analysis of Forest Laboratories' R&D pipeline, clinical trial activity, patents, FDA submissions, and includes profiles of Forest's key products. In Forest's January 2014 financial conference call they noted that Research and Development spending for the current quarter was approximately $220 million as compared to $325 million reported in the third quarter last year, a reported decrease of 33%,' explained Andrew Schafer, President of ISR. We certainly did not see Forest's recent acquisition of Aptalis coming or the more recent offer by Actavis to buy Forest Labs for $25 Billion. However, we did realize that Forest was a company in play, Schafer continued. The report provides pharmaceutical companies and service providers with a look into Forest's individual drug sales and company financial condition over the past four years, the number, length, and patient enrollment of clinical trials segmented by phase and trial type, and Forest's R&D pipeline with mechanism of action identified. This data will help service providers better understand Forest's clinical pipeline while giving sponsors an idea of how these competing compounds may affect the launch of similar products. Key Topics Covered: 1. Copyright and Usage Guidelines 2. Background and strategy 3. Financial condition 4. R&D pipeline overview 5. Clinical trial activity 6. Patents 7. FDA submissions 8. Key product profiles 9. Summary For more information visit http://www.researchandmarkets.com/research/sh...orest_labs
FRX: 99.00 (-0.77)
Helius Medical Technologies Appoints Dr. Jonathan Sackier as Chairman of Scientific Advisory Board
ACCESSWIRE - Mon Oct 27, 12:30PM CDT
Newtown, PA / ACCESSWIRE / October 27, 2014 / Helius Medical Technologies, Inc. (CSE: HSM) ("HMT", "Helius" or the "Company"
a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, is pleased to announce today that noted British surgeon Dr. Jonathan Sackier has agreed to serve as Chairman of the company's newly formed Scientific Advisory Board. FRX: 99.00 (-0.77)
Thyroid Cancer Market Analysis - API Manufacturers and Phase III Pipeline Assessment 2014-2015
M2 - Thu Oct 02, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5sgp9d/thyroid_cancer) has announced the addition of the "Thyroid Cancer Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Thyroid Cancer- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Exelixis, Inc. - Pfizer Inc. - Genzyme Corporation - Bracco Diagnostics Inc. - Mallinckrodt plc - Sandoz Inc. - Forest Laboratories, Inc. - Institut Biochimique SA - Jubilant DraxImage Inc. For more information visit http://www.researchandmarkets.com/research/5s...oid_cancer
PFE: 34.64 (-0.23), FRX: 99.00 (-0.77), EXEL: 2.48 (+0.20)
Alcohol Addiction Market Analysis - Global API Manufacturers and Phase III Pipeline Assessment 2014-2015
M2 - Thu Oct 02, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grf3gh/alcohol) has announced the addition of the "Alcohol Addiction- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Alcohol Addiction- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Alkermes Plc - Duramed Pharmaceuticals, Inc. - Odyssey Pharmaceuticals, Inc. - Teva Pharmaceuticals USA, Inc. - Forest Laboratories, Inc. - Valeant Pharmaceuticals International, Inc. For more information visit http://www.researchandmarkets.com/research/grf3gh/alcohol
ALKS: 71.40 (-1.89), FRX: 99.00 (-0.77), VRX.TO: 207.95 (-1.47)
Influenza A Infections Market Analysis 2014-2015 - API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Oct 02, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tm72pp/influenza_a) has announced the addition of the "Influenza A Infections Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Influenza A Infections- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Forest Laboratories, Inc. - Caraco Pharmaceutical Laboratories, Ltd. - Endo Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tm...nfluenza_a
ENDP: 84.01 (+1.12), FRX: 99.00 (-0.77)
Depression Market Analysis - Global API Manufacturers and Phase III Pipeline Assessment, 2014-2015
M2 - Thu Oct 02, 3:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f52zs9/depression_market) has announced the addition of the "Depression Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Depression Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Forest Laboratories, Inc. - Pfizer Inc. - Abbott Laboratories - Sanofi - Eli Lilly and Company - Bristol-Myers Squibb Company - sanofi-aventis U.S. LLC. - Validus Pharmaceuticals LLC - AstraZeneca PLC - Valeant Pharmaceuticals International, Inc. - Teva Pharmaceutical Industries Limited - Lilly USA, LLC - Janssen Pharmaceutical Ltd - Merck & Co., Inc. - Otsuka Pharmaceutical Co., Ltd. - Teva Pharmaceuticals USA, Inc. - Novartis AG - F. Hoffmann-La Roche Ltd. - AstraZeneca Pharmaceuticals, LP - Baxter Healthcare Corporation - GlaxoSmithKline LLC - Solvay Pharmaceuticals, Inc. - Roxane Laboratories, Inc. - Bayer HealthCare Pharmaceuticals Inc. - Solvay Pharma Inc. - New River Pharmaceuticals, Inc. - GlaxoSmithKline plc - Bioniche Pharma Group Limited - Dr. Reddy's Laboratories Limited - Orchid Chemicals & Pharmaceuticals Ltd For more information visit http://www.researchandmarkets.com/research/f5...ion_market
ABT: 46.09 (+0.87), PFE: 34.64 (-0.23), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), FRX: 99.00 (-0.77), VRX.TO: 207.95 (-1.47), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Network with Astellas, GSK, J&J, and the National Pharmacy Association | European Pharmaceutical P&R 2014
PRWeb - Sat Sep 27, 3:01AM CDT
Just under 3 weeks remain until the doors open to host the popular industry conference on European Pharmaceutical Pricing and Reimbursement. this global event will feature attendees from Belgium, Czech Republic, Denmark, France, Germany, Italy, Netherlands, Sweden, Switzerland, United Kingdom and USA.
JNJ: 99.62 (+1.18), FRX: 99.00 (-0.77)
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023
M2 - Thu Sep 25, 5:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9vx7ff/pharmapoint) has announced the addition of the "PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023" report to their offering. Product Launches and Patent Expiries to Push Major Depressive Disorder Treatment Market through Fluctuating Growth Period by 2023 This report provides an overview of Major Depressive Disorder (MDD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis and current treatment options. The key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the MDD therapeutics market. The therapeutics market for Major Depressive Disorder (MDD) will face a dynamic phase up until the end of 2023, thanks to the potential launch of new treatments following the patent expirations of top-selling products, says a new report from research and consulting firm The authors. According to the company's latest report*, the MDD treatment market achieved sales of approximately $9.3 billion in 2013 across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan) and Australia. These sales will witness minimal growth by the end of 2023, reaching an estimated $9.7 billion, at a Compound Annual Growth Rate (CAGR) of 0.39%. However, The authors forecasts that the market value will first undergo a decline until 2017, with sales dropping to $7.3 billion. This can be attributed mainly to the expirations of patents for Eli Lilly's Cymbalta, Otsuka Pharmaceutical/BMS' Abilify and AstraZeneca's Seroquel XR. The authors states that there are already seven products in the late-stage pipeline that could enter the MDD market during the forecast period. These include adjunctive therapies, such as Otsuka/Lundbeck's brexpiprazole, Forest (Actavis)/Gedeon Richter/Mitsubishi Tanabe Pharma's cariprazine, Alkermes's ALKS-5461 and Naurex's GLYX-13, along with antidepressant therapies, including Euthymics Bioscience's amitifadine, Lundbeck/Takeda's tedatioxetine and e-Therapeutics' ETS6103. Koutsokeras continues: All seven of these pipeline drugs show promise as safer and more efficacious treatments for MDD patients, while GLYX-13 and ETS6103 in particular boast the potential to provide rapid antidepressant effects. With their ability to address some of the MDD treatment market's key unmet needs, we believe that these products' launches could well spark its return to growth in 2018. Other driving factors behind the reversal in its decline will be the increasing uptake of Lundbeck/Takeda's Brintellix, combined with the expanding number of MDD prevalent cases that we expect to see by the end of 2023. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview - Etiology and Pathophysiology - Classification - Symptoms and Subtypes of Major Depressive Disorder - Prognosis - Quality of Life 4 Epidemiology - Risk Factors and Comorbidities - Global and Historical Trends - Forecast Methodology - Epidemiological Forecast for MDD (2013-2023) 5 Disease Management - Diagnosis - Treatment Guidelines and Leading Prescribed Drugs - Clinical Practice 6 Competitive Assessment - Lexapro (Escitalopram) - Viibryd (Vilazodone) - Other Selective Serotonin Reuptake Inhibitors - Effexor (Venlafaxine) - Cymbalta (Duloxetine) - Pristiq (Desvenlafaxine) - Fetzima (Levomilnacipran) - Savella (Milnacipran) - Norepinephrine-Dopamine Reuptake Inhibitors - Noradrenaline and Specific Serotonergic Antidepressants - Monoamine Oxidase Inhibitors - Tricyclic Antidepressants - Brintellix (Vortioxetine) - Abilify (Aripiprazole) - Seroquel XR (Quetiapine) 7 Unmet Needs and Opportunities - More Effective Pharmacotherapies - More Favorable Side Effect Profiles - Rapid Onset of Antidepressant Effects - Personalized Treatment Approach 8 Pipeline Assessment - Brexpiprazole (OPC-34712) - Cariprazine (RGH-188) - ALKS-5461 - Amitifadine (EB-1010) - GLYX-13 - Tedatioxetine (Lu AA24530) - ETS6103 - Other Drugs in Development 9 Current and Future Players - Lundbeck - Forest Laboratories (Actavis) - Eli Lilly - Pfizer - Otsuka Pharmaceutical - AstraZeneca - Takeda Pharmaceutical - Alkermes - Euthymics Bioscience - Naurex - e-Therapeutics 10 Market Outlook - Global - US - France - Germany - Italy - Spain - UK - Japan - Australia 11 Appendix For more information visit http://www.researchandmarkets.com/research/9v...harmapoint
LLY: 70.56 (+0.03), ALKS: 71.40 (-1.89), FRX: 99.00 (-0.77)
Acute Inflammation Therapeutics Pipeline Report 2014 - 9 Companies & 10 Drug Profiles
M2 - Wed Sep 10, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/849tzx/acute) has announced the addition of the "Acute Inflammation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Inflammation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - BioLineRx, Ltd. - Actelion Ltd - Forest Laboratories, Inc. - Italfarmaco S.p.A. - Alligator Bioscience AB - Anacor Pharmaceuticals, Inc. - Omeros Corporation - Dompe Farmaceutici S.p.A. - Peptinnovate Limited Drug Profiles - ACT-389949 - ATL-1222 - CGEN-856 - ADC-1004 - DF-2156A - Selective Inhibitor of Pro Inflammatory Cytokine - AN-3485 - PIN-201104 - Small Molecule Targeting GPR32 for Acute Inflammation - Distamycin Derivatives For more information visit http://www.researchandmarkets.com/research/849tzx/acute
ANAC: 40.76 (-0.07), FRX: 99.00 (-0.77), OMER: 20.63 (+0.13)
Why Endo International Can Deliver Solid Rewards With Minimal Risk
at The Street - Tue Sep 02, 1:31PM CDT
With the recent deal for DAVA, Endo is now one of the best health care stocks to own.
ENDP: 84.01 (+1.12), MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58), FRX: 99.00 (-0.77)
RiverVest Venture Partners' Otonomy Completes $100 Million Initial Public Offering
Business Wire - Wed Aug 13, 9:23AM CDT
Otonomy, a RiverVest Fund II portfolio company that develops drug therapies for the inner and middle ear, announced today its $100 million initial public offering.
BSX: 14.98 (+0.24), ABT: 46.09 (+0.87), BCR: 175.38 (+0.50), PFE: 34.64 (-0.23), FRX: 99.00 (-0.77), OTIC: 31.14 (+0.13)
The Impact of Genericization in the Unipolar Depression Market Will be Tempered by the Continued Uptake of Novel Antidepressants and Antipsychotics
PR Newswire - Wed Aug 13, 9:00AM CDT
Decision Resources Group finds that in the unipolar depression* market, the expanding use of two recently approved therapies--Lundbeck/Takeda Pharmaceutical's Brintellix (vortioxetine), Actavis (formerly Forest Laboratories)/Pierre Fabre's Fetzima (levomilnacipran ER)--together with the forecasted launch of Otsuka Pharmaceutical/Lundbeck's brexpiprazole in the major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will offset a steep near-term decline in sales resulting from the loss of market exclusivity for the two key drugs prescribed for unipolar depression--duloxetine (Eli Lilly/Shionogi's Cymbalta/Xeristar, generics) and the atypical antipsychotic Abilify (Bristol-Myers Squibb/Otsuka Pharmaceutical's aripiprazole). By 2023, total major-market sales for unipolar depression will reach under $10 billion.
LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), FRX: 99.00 (-0.77)
Sponsor And CRO Finalists Announced For Annual Society For Clinical Research Sites Eagle Award
PR Newswire Europe - Mon Aug 11, 11:30AM CDT
- AstraZeneca, Boehringer Ingelheim, Eli Lilly & Company, Ferring Pharmaceuticals, Inc., Forest Laboratories, Inc., GlaxoSmithKline, Novartis, Novo Nordisk, Pearl Therapeutics, Pfizer, Sanofi, Chiltern International, ICON plc, INC Research, inVentiv Health, Parexel International, Pharmaceutical Research Associates (PRA), Quintiles, and Target Health Inc.
NVO: 43.76 (+0.61), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), FRX: 99.00 (-0.77), NVS: 102.20 (-0.17)
Adamas Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 07, 3:44PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported net income attributable to common stockholders of $16.4 million, or $0.88 per share on a fully diluted basis, for the quarter ended June 30, 2014. In the same period last year, the company reported a net loss attributable to common stockholders of $3.4 million, or $0.35 per share on a fully diluted basis. The difference between the two periods was primarily the result of the recognition of revenue associated with the collaboration with Forest Laboratories, Inc. (acquired by Actavis plc in July 2014).
ADMS: 16.98 (+0.03), FRX: 99.00 (-0.77)
